2014 was a tough year for GlaxoSmithKline. Its revenues and profits were off significantly. Its operating profit was off nearly 50% in pounds--and, as it turns out, so was CEO Andrew Witty's pay. In fact he took a 46% whack to his compensation.
GlaxoSmithKline says Sir Philip Hampton is free to take the reins in May.
After nearly a year off the shelves, GlaxoSmithKline's diet pill alli--recalled after reports of tampering--is back in most U.S. stores, and it's got some updates that should make any future tampering easier to spot.
UPDATED: NIH funds studies of J&J's and GSK's injectable HIV meds, says daily pills lead to noncompliance
In bid to improve patient adherence, the U.S. National Institutes of Health is funding and helping run two clinical trials of long-acting injectable HIV candidates being developed by Johnson & Johnson's Janssen and GlaxoSmithKline.
Indian drugmaker Lupin announced two separate developments in its asthma drug delivery segment, launching one product in the U.S. and signing a development agreement for a generic version of GlaxoSmithKline's Advair Diskus, which would be commercialized in North America and other markets.
Just who is the neuroscientist and university professor AstraZeneca has nominated to its board of directors? A sometime critic of the pharma industry, the Financial Times points out.
Whether it's a reorg at a big company like Sanofi or GlaxoSmithKline, or a biotech like Constellation, I rely quite a bit on the big global network of readers we've gathered over the past 13 years to keep me posted on the things that companies don't put in a press release.
FiercePharmaAsia rounds up company activity in Asia across pharmaceuticals, biotech and devices to stay abreast of deal making and provide insight on partnerships and disputes in the works.
The GlaxoSmithKline officials accused of orchestrating its $489 million Chinese bribery scandal may have dodged prison sentences in the country, but a Shanghai health official linked to the British pharma won't be so lucky.
GlaxoSmithKline's sputtering U.S. sales gave the company a black eye with investors. Now, the company's U.S. chief is stepping down. Deirdre Connelly is out the door, the company told employees on Tuesday, with SVP Jack Bailey rising to take her place.